Piramal Pharma Ltd. posted a consolidated net loss of Rs 136 crore for the third quarter, weighed down by inventory-related pressures that offset steady operational activity across its business segments. Elevated inventory levels and associated costs strained margins, overshadowing stable demand in contract development and manufacturing services and consumer healthcare. The results underscore the sensitivity of pharmaceutical earnings to working capital management amid volatile global demand conditions.